STOCK TITAN

Purple Biotech Ltd. American Depositary Shares - PPBT STOCK NEWS

Welcome to our dedicated page for Purple Biotech Ltd. American Depositary Shares news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech Ltd. American Depositary Shares stock.

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company based in Rehovot, Israel, dedicated to developing innovative cancer therapies that harness the tumor microenvironment to overcome immune evasion and drug resistance. The company's oncology pipeline includes two main drug candidates, CM24 and NT219, along with a pioneering platform of conditionally-activated tri-specific antibodies.

CM24 is a multi-functional immune checkpoint inhibitor undergoing Phase 2 clinical trials for the treatment of pancreatic ductal adenocarcinoma (PDAC). This study, in collaboration with Bristol Myers Squibb, is evaluating CM24 combined with nivolumab and chemotherapy as a second-line treatment. The primary endpoint is overall survival, with interim results expected by mid-2024 and topline data by the end of the same year.

NT219 is a small molecule dual inhibitor targeting IRS1/2 and STAT3. It has shown promising results in a Phase 1/2 dose escalation study for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). A Phase 2 study is planned for NT219 in combination with cetuximab, set to begin in the first half of 2024.

Additionally, Purple Biotech’s tri-specific antibody platform aims to conditionally activate T cells and natural killer (NK) cells within the tumor microenvironment. The platform's lead candidate, IM1240, targets 5T4, a tumor-associated antigen, and is designed to induce a localized immune response while minimizing off-tumor side effects.

Recent financial reports indicate that Purple Biotech has a solid cash runway into the first half of 2025, thanks to strategic funding and partnerships. The company’s research and development expenses have seen a slight increase due to ongoing clinical trials, while selling, general, and administrative expenses have decreased.

For more detailed information and the latest updates, visit Purple Biotech’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
management
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.21%
Tags
conferences clinical trial

FAQ

What is the current stock price of Purple Biotech Ltd. American Depositary Shares (PPBT)?

The current stock price of Purple Biotech Ltd. American Depositary Shares (PPBT) is $0.4505 as of September 6, 2024.

What is the market cap of Purple Biotech Ltd. American Depositary Shares (PPBT)?

The market cap of Purple Biotech Ltd. American Depositary Shares (PPBT) is approximately 14.3M.

What is Purple Biotech Ltd. focused on?

Purple Biotech Ltd. focuses on developing first-in-class therapies to overcome tumor immune evasion and drug resistance, particularly for cancer treatment.

What are the main drug candidates in Purple Biotech's pipeline?

The main drug candidates are CM24 and NT219. CM24 is an immune checkpoint inhibitor for pancreatic cancer, while NT219 is a dual inhibitor targeting IRS1/2 and STAT3 for head and neck cancer.

What is CM24?

CM24 is a multi-functional immune checkpoint inhibitor currently in Phase 2 clinical trials for treating pancreatic ductal adenocarcinoma (PDAC).

What is NT219?

NT219 is a small molecule dual inhibitor targeting IRS1/2 and STAT3, currently being tested in combination with cetuximab for head and neck cancer.

What is unique about Purple Biotech’s tri-specific antibody platform?

This platform conditionally activates T cells and NK cells within the tumor microenvironment, aiming to induce a strong localized immune response while minimizing off-tumor side effects.

What recent milestones has Purple Biotech achieved?

Recent milestones include completing patient enrollment ahead of schedule for the Phase 2 CM24 study and determining the recommended Phase 2 dose for NT219 in combination with cetuximab.

What are Purple Biotech's financial highlights?

Purple Biotech has a cash runway into the first half of 2025, with increased research and development expenses due to ongoing trials and decreased selling, general, and administrative expenses.

Who are Purple Biotech's key partners?

Purple Biotech collaborates with Bristol Myers Squibb for the Phase 2 clinical trials of CM24.

Where is Purple Biotech headquartered?

Purple Biotech is headquartered in Rehovot, Israel.

Where can I find more information about Purple Biotech?

You can find more information on Purple Biotech’s website at https://purple-biotech.com/.

Purple Biotech Ltd. American Depositary Shares

Nasdaq:PPBT

PPBT Rankings

PPBT Stock Data

14.25M
321.60M
3.27%
5.93%
1.21%
Biotechnology
Healthcare
Link
United States of America
Rehovot